Bajaj Healthcare soars on launching posaconazole API

Image
Capital Market
Last Updated : May 28 2021 | 11:32 AM IST

Bajaj Healthcare surged 6.01% to Rs 674.30 after the company announced the launch of posaconazole API, commonly used for treating mucormycosis (black fungus) infections in COVID-19 patients.

The company has received approval from FDA Gandhi Nagar, Gujarat (India), to manufacture and market Posaconazole API as approved medication for treating Mucormycosis in India. The firm will commence its commercial production from first week of June 2021.

The company has successfully developed the active pharmaceutical ingredient (API) for Posaconazole through its own in-house R&D team. The drug will be available as a prescription-based medication, with recommended doses.

Posaconazole is a triazole antifungal agent indicated for treating Mucormycosis patients popularly known as Black Fungus in post-COVID complications.

Black fungus is a deadly fungal infection and has triggered a new health challenge in the country. More than 11,000 cases of black fungal infection have been reported from different parts, forcing state governments to declare it an epidemic.

Anil Jain, joint managing director, Bajaj Healthcare said We are pleased to add Posaconazole API to our growing product portfolios. The second waves of coronavirus is more aggressive and bigger in number than the first.

According to doctors, the fungal infection that has emerged during the second wave has been widely linked with excessive usage of steroids and uncontrolled diabetes in coronavirus positive patients.

We hope the availability of an effective treatment such as Posaconazole will considerably ease the pressure and offer patients much needed and timely therapy option."

Bajaj Healthcare is a leading manufacturer of APIs, intermediates and formulations. It specializes in manufacturing of of amino acids, intermediates, API, formulations & nutraceuticals.

The company's net profit surged to Rs 326.1% to Rs 26.42 crore on a 79.6% rise in net sales to Rs 178.33 crore in Q3 FY21 over Q3 FY20.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 28 2021 | 11:01 AM IST

Next Story